Is Lercanidipine Hydrochloride compatible with breastfeeding? Do we have alternatives for Lercanidipine Hydrochloride?

Lercanidipine Hydrochloride

June 4, 2016 (Low Risk)

At latest update no published data were found on excretion into breast milk.

Evidence on other antihypertensive drugs of the same family with similar structure, pharmacokinetics and action profile (nifedipine, nimodipine, nicardipine) has shown that they are excreted into milk in non-significant amount.
Its high plasma protein binding capacity makes it unlikely any passage to the milk, however, its high lipid solubility facilitates excretion into it.

Although it has a low oral bioavailability, it may increase to four times if administered with a fatty meal, which would increase the oral absorption in the infant.

Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug should be used, especially during the neonatal period and/or in case of premature infants.

Alternatives

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Synonyms

  • Masnidipine

Writings

  • Λερκανιδιπίνη Υδροχλωρική (Greek)
  • Лерканидипина Гидрохлорид (Cyrillic)
  • 塩酸レルカニジピン (Japanese)
  • C36H41N3O6,HCl (Molecular formula)

References

  1. ARTG. Lercanidipine. Product Monograph. 2014 Full text (in our servers)
  2. AEMPS. Lercanidipino. Ficha técnica. 2011 Full text (in our servers)